Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

 Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

Shots:

  • The P-III EVOLVE-MS-2 study assessing the GI tolerability of Diroximel Fumarate (462mg, bid) vs Tecfidera (dimethyl fumarate, 240 mg, bid) in 506 patients with RRMS
  • The P-III EVOLVE-MS-2 study results demonstrated superiority in gastrointestinal (GI) tolerability with a symptom intensity score ≥2 on the IGISIS rating scale and low discontinuation rates of <1% due to GI adverse events
  • Diroximel fumarate is a fumarate therapy designed to convert to monomethyl fumarate in the body and is under the US FDA review with its expected PDUFA date in Q4’19. Post-FDA’s approval, Biogen plans to market diroximel fumarate under the name Vumerity

Click here to­ read full press release/ article | Ref: Biogen | Image: Shigotoba

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post